美国Aegerion 
 

Aegerion Pharmaceuticals aspires to change the way rare, genetic lipid disorders are treated. We are an emerging biopharmaceutical company focused on the development and commercialization of a novel life-altering therapeutic for debilitating and often fatal orphan diseases. The Company’s first product candidate in late-stage clinical development, lomitapide, is a small molecule, once-a-day, oral therapy to treat a severe form of hypercholesterolemia called HoFH.